Publications by authors named "Paul Moser"

Claim this Profile
S
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
José-Francisco Rocha, Ana Santos, Helena Gama, Paul Moser, Amílcar Falcão

Clin Pharmacol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction to the EQIPD quality system.
Anton Bespalov, René Bernard, Anja Gilis, Björn Gerlach, Javier Guillén, Paul Moser

Elife· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology profile of F17464, a dopamine D receptor preferential antagonist.
Cristina Cosi, Jean-Claude Martel, Agnès L Auclair, Ginetta Collo, Laura Cavalleri, Paul C Moser

Eur J Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-clinical toxicology evaluation of BIA 10-2474.
A Wallace Hayes, Klaus Weber, Paul Moser, Patrício Soares-da-Silva

Crit Rev Toxicol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory safety pharmacology evaluation of BIA 10-2474.
A Wallace Hayes, Peter Pressman, Paul Moser, Patrício Soares-da-Silva

J Pharmacol Toxicol Methods· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474.
Maria-João Bonifácio, Filipa Sousa, Cátia Aires, Ana I Loureiro, Carlos Fernandes-Lopes, Paul Moser

Br J Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Out of Control? Managing Baseline Variability in Experimental Studies with Control Groups.
Paul Moser

Handb Exp Pharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
Takashi Kitajima, Shintaro Mizote, Maria João Bonifácio, Takeo Umemura, Kazuhiro Yoneda, Paul Moser

Neuropharmacology· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.
Anton Bespalov, Thomas Steckler, Bruce Altevogt, Elena Koustova, Phil Skolnick, Paul Moser

Nat Rev Drug Discov· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating negative-symptom-like behavioural changes in developmental models of schizophrenia.
Paul Moser

Eur Neuropsychopharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies.
James J Lynch, Vincent Castagné, Paul C Moser, Scott W Mittelstadt

J Pharmacol Toxicol Methods· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous evaluation of drug withdrawal in the rat using telemetry: effects of morphine and chlordiazepoxide.
Christelle Froger-Colléaux, Sonia Rompion, Philippe Guillaume, Roger D Porsolt, Vincent Castagné, Paul Moser

J Pharmacol Toxicol Methods· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current approaches and issues in non-clinical evaluation of abuse and dependence.
Paul Moser, Toni Wolinsky, Vincent Castagné, Mark Duxon

J Pharmacol Toxicol Methods· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electroencephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents.
David C Henshall, Nick Dürmüller, H Steve White, Robert Williams, Paul Moser

Neuropsychiatr Dis Treat· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice.
Vincent Castagné, Paul Moser, Sylvain Roux, Roger D Porsolt

Curr Protoc Neurosci· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How good are current approaches to nonclinical evaluation of abuse and dependence?
Paul Moser, Toni Wolinsky, Mark Duxon, Roger D Porsolt

J Pharmacol Exp Ther· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical behavioral models for predicting antipsychotic activity.
Vincent Castagné, Paul C Moser, Roger D Porsolt

Adv Pharmacol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Behavioral indices in antipsychotic drug discovery.
Roger D Porsolt, Paul C Moser, Vincent Castagné

J Pharmacol Exp Ther· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice.
Vincent Castagné, Paul Moser, Sylvain Roux, Roger D Porsolt

Curr Protoc Pharmacol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse.
Vincent Castagné, Roger D Porsolt, Paul Moser

Eur J Pharmacol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous stimulation of dopaminergic receptors by rotigotine does not interfere with the sleep-wake cycle in the rat.
Dieter Scheller, Nick Dürmüller, Paul Moser, Roger D Porsolt

Eur J Pharmacol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk.
Niklaus Dürmüller, Philippe Guillaume, Pierre Lacroix, Roger D Porsolt, Paul Moser

J Pharmacol Toxicol Methods· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
Paul C Moser, Olivier E Bergis, Samir Jegham, Alistair Lochead, Elee Duconseille

J Pharmacol Exp Ther· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis